Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
65.50
+0.34 (+0.52%)
Streaming Delayed Price
Updated: 3:15 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
May 02, 2023
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.
Via
Investor's Business Daily
Why Incyte Shares Are Falling Today
May 02, 2023
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the
Via
Benzinga
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 02, 2023
From
Incyte
Via
Business Wire
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
May 01, 2023
From
Incyte
Via
Business Wire
Earnings Outlook For Incyte
May 01, 2023
Via
Benzinga
Ominous Death Cross Forms On Incyte's Chart
April 13, 2023
Via
Benzinga
What 13 Analyst Ratings Have To Say About Incyte
March 28, 2023
Via
Benzinga
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
March 24, 2023
The company had hoped to gain approval for an extended-release version of its biggest drug.
Via
Investor's Business Daily
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
April 21, 2023
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain...
Via
Benzinga
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 20, 2023
From
Incyte
Via
Business Wire
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
Incyte to Present at Upcoming Investor Conferences
April 18, 2023
From
Incyte
Via
Business Wire
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 16, 2023
From
Incyte and MorphoSys U.S. Inc.
Via
Business Wire
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
April 14, 2023
One executive called this the most "damaging" decision in five decades.
Via
Investor's Business Daily
Incyte to Report First Quarter Financial Results
April 11, 2023
From
Incyte
Via
Business Wire
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday
April 10, 2023
Micron and Charles Schwab were among the top performers.
Via
Investor's Business Daily
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
April 10, 2023
Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
April 10, 2023
Via
Benzinga
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
April 10, 2023
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...
Via
Benzinga
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
March 27, 2023
From
Incyte
Via
Business Wire
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Via
Benzinga
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
From
Incyte
Via
Business Wire
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
Via
Benzinga
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
From
Incyte
Via
Business Wire
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
The cancer-focused biotech delivered a strong earnings report.
Via
The Motley Fool
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
March 14, 2023
From
Incyte Corporation
Via
Business Wire
Which S&P 500 Stocks Look Most Attractive Now?
March 08, 2023
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.